세계의 암 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)
Global Cancer Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
상품코드:1820525
리서치사:Value Market Research
발행일:2025년 08월
페이지 정보:영문 128 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 암 백신 시장은 대폭적인 성장을 이루어 시장 규모는 2024년 95억 9,000만 달러에서 2033년에는 249억 5,000만 달러로 급증하고, 예측 기간중 연평균 복합 성장률(CAGR)은 11.21%를 나타낼 것으로 예측됩니다.
암 치료에서 면역요법이 주목받으면서 암 백신 시장은 빠르게 성장하고 있습니다. 면역체계를 자극해 종양세포를 인식하고 공격하도록 설계된 암 백신은 자궁경부암, 전립선암, 흑색종 등 다양한 암을 타겟으로 하는 예방형과 치료형이 있습니다. 펩타이드 기반 백신, 수지상 세포 백신, mRNA 백신 등 백신 플랫폼의 혁신은 특이성, 효능, 안전성 프로파일을 향상시키고 있습니다.
암 백신과 체크포인트 억제제 및 개인 맞춤형 의료 접근법과의 통합으로 임상 적용이 확대되고 있습니다. 바이오마커 식별과 유전체 프로파일링의 발전은 환자 계층화 및 백신 맞춤화를 지원합니다. 규제 당국의 승인과 성공적인 임상시험이 시장 성장을 가속화하고 있습니다. 또한, 암 발병률과 인식 증가는 새로운 면역요법에 대한 수요를 촉진하고 있습니다.
생명공학 기업, 연구기관, 의료 서비스 제공업체 간의 협력 관계는 기술 혁신과 상용화를 촉진하고 있습니다. 면역종양학의 발전과 함께 암 백신 시장은 크게 성장하고 있으며, 환자 치료 결과를 개선할 수 있는 유망한 치료 옵션을 제공합니다.
목차
제1장 서문
제2장 주요 요약
시장 하이라이트
세계 시장 현황
제3장 암 백신 - 산업 분석
서론 : 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
업계 동향
Porter의 Five Forces 분석
시장 매력 분석
제4장 밸류체인 분석
밸류체인 분석
원재료 분석
원재료 리스트
원재료 제조업체 리스트
주요 원재료 가격 동향
잠재적 바이어 리스트
마케팅 채널
직접 마케팅
간접 마케팅
마케팅 채널 발전 동향
제5장 세계의 암 백신 시장 분석 : 백신 유형별
백신 유형별 개요
과거 및 예측 데이터 분석 : 백신 유형별
암 예방 백신
치료용 암 백신
기타
제6장 세계의 암 백신 시장 분석 : 적응증 유형별
개요 : 적응증 유형별
과거 및 예측 데이터 분석 : 적응증 유형별
전립선암
방광암
흑색종
자궁경부암
기타
제7장 세계의 암 백신 시장 분석 : 기술 유형별
기술 유형별 개요
과거 및 예측 데이터 분석 : 기술 유형별
재조합 암 백신
전체 세포 암 백신
바이러스 벡터 및 DNA 암 백신
기타 기술
제8장 세계의 암 백신 시장 분석 : 지역별
지역별 전망
서론
북미의 판매 분석
개요, 분석과 예측
북미 : 부문별
북미 국가별
미국
캐나다
멕시코
유럽의 판매 분석
개요, 분석과 예측
유럽 : 부문별
유럽 국가별
영국
프랑스
독일
이탈리아
러시아
기타 유럽
아시아태평양의 판매 분석
개요, 분석과 예측
아시아태평양 : 부문별
아시아태평양 국가별
중국
인도
일본
한국
호주
동남아시아
기타 아시아태평양
라틴아메리카의 판매 분석
개요, 분석과 예측
라틴아메리카 : 부문별
라틴아메리카 국가별
브라질
아르헨티나
페루
칠레
기타 라틴아메리카
중동 및 아프리카의 판매 분석
개요, 분석과 예측
중동 및 아프리카 : 부문별
중동 및 아프리카 국가별 리스트
사우디아라비아
아랍에미리트(UAE)
이스라엘
남아프리카공화국
기타 중동 및 아프리카
제9장 암 백신 기업 경쟁 구도
암 백신 시장 경쟁
파트너십/제휴/합의
인수합병(M&A)
신제품 출시
기타 개발
제10장 기업 개요
주요 기업의 시장 점유율 분석
시장 집중도
Merck & Co. Inc.
GSK Plc
Dendreon Pharmaceuticals LLC
Dynavax Technologies Corporation
Ferring B.V.
Amgen Inc.
Moderna Inc.
Sanofi
AstraZeneca
Bristol Myers Squibb
LSH
영문 목차
영문목차
Global Cancer Vaccines Market is poised for a significant growth, with market size projected to surge from USD 9.59 Billion in 2024 to USD 24.95 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 11.21% during the forecast period.
The cancer vaccines market is advancing rapidly as immunotherapy gains prominence in oncology treatment paradigms. Cancer vaccines, designed to stimulate the immune system to recognize and attack tumor cells, include prophylactic and therapeutic types targeting various cancers such as cervical, prostate, and melanoma. Innovations in vaccine platforms, including peptide-based, dendritic cell, and mRNA vaccines, are enhancing specificity, efficacy, and safety profiles.
The integration of cancer vaccines with checkpoint inhibitors and personalized medicine approaches is expanding clinical applications. Advances in biomarker identification and genomic profiling support patient stratification and vaccine customization. Regulatory approvals and clinical trial successes are accelerating market growth. Additionally, increasing cancer incidence and awareness are driving demand for novel immunotherapies.
Collaborations among biotech firms, research institutions, and healthcare providers are fostering innovation and commercialization. As immuno-oncology evolves, the cancer vaccines market is positioned for significant growth, offering promising therapeutic options to improve patient outcomes.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
LIST OF SEGMENTS COVERED
This section of the Cancer Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
3.7.1 Market Attractiveness Analysis By Vaccine Type
3.7.2 Market Attractiveness Analysis By Indication Type
3.7.3 Market Attractiveness Analysis By Technology Type
3.7.4 Market Attractiveness Analysis By Regions
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL CANCER VACCINES MARKET ANALYSIS BY VACCINE TYPE
5.1. Overview By Vaccine Type
5.2. Historical and Forecast Data Analysis By Vaccine Type
5.3. Preventive Cancer Vaccines Historic and Forecast Sales By Regions
5.4. Therapeutic Cancer Vaccines Historic and Forecast Sales By Regions
5.5. Others Historic and Forecast Sales By Regions
6. GLOBAL CANCER VACCINES MARKET ANALYSIS BY INDICATION TYPE
6.1. Overview By Indication Type
6.2. Historical and Forecast Data Analysis By Indication Type
6.3. Prostate Cancer Historic and Forecast Sales By Regions
6.4. Bladder Cancer Historic and Forecast Sales By Regions
6.5. Melanoma Historic and Forecast Sales By Regions
6.6. Cervical Cancer Historic and Forecast Sales By Regions
6.7. Other Historic and Forecast Sales By Regions
7. GLOBAL CANCER VACCINES MARKET ANALYSIS BY TECHNOLOGY TYPE
7.1. Overview By Technology Type
7.2. Historical and Forecast Data Analysis By Technology Type
7.3. Recombinant Cancer Vaccines Historic and Forecast Sales By Regions
7.4. Whole-cell Cancer Vaccines Historic and Forecast Sales By Regions
7.5. Viral Vector and DNA Cancer Vaccines Historic and Forecast Sales By Regions
7.6. Other Technologies Historic and Forecast Sales By Regions
8. GLOBAL CANCER VACCINES MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
8.3.1 Overview, Historic and Forecast Data Sales Analysis
8.3.2 North America By Segment Sales Analysis
8.3.3 North America By Country Sales Analysis
8.3.4 United States Sales Analysis
8.3.5 Canada Sales Analysis
8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
8.4.1 Overview, Historic and Forecast Data Sales Analysis
8.4.2 Europe By Segment Sales Analysis
8.4.3 Europe By Country Sales Analysis
8.4.4 United Kingdom Sales Analysis
8.4.5 France Sales Analysis
8.4.6 Germany Sales Analysis
8.4.7 Italy Sales Analysis
8.4.8 Russia Sales Analysis
8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
8.5.1 Overview, Historic and Forecast Data Sales Analysis
8.5.2 Asia Pacific By Segment Sales Analysis
8.5.3 Asia Pacific By Country Sales Analysis
8.5.4 China Sales Analysis
8.5.5 India Sales Analysis
8.5.6 Japan Sales Analysis
8.5.7 South Korea Sales Analysis
8.5.8 Australia Sales Analysis
8.5.9 South East Asia Sales Analysis
8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
8.6.1 Overview, Historic and Forecast Data Sales Analysis
8.6.2 Latin America By Segment Sales Analysis
8.6.3 Latin America By Country Sales Analysis
8.6.4 Brazil Sales Analysis
8.6.5 Argentina Sales Analysis
8.6.6 Peru Sales Analysis
8.6.7 Chile Sales Analysis
8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
8.7.1 Overview, Historic and Forecast Data Sales Analysis
8.7.2 Middle East & Africa By Segment Sales Analysis
8.7.3 Middle East & Africa By Country Sales Analysis
8.7.4 Saudi Arabia Sales Analysis
8.7.5 UAE Sales Analysis
8.7.6 Israel Sales Analysis
8.7.7 South Africa Sales Analysis
8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE CANCER VACCINES COMPANIES
9.1. Cancer Vaccines Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10. COMPANY PROFILES OF CANCER VACCINES INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Merck & Co. Inc.
10.3.1 Company Overview
10.3.2 Company Revenue
10.3.3 Products
10.3.4 Recent Developments
10.4. GSK Plc
10.4.1 Company Overview
10.4.2 Company Revenue
10.4.3 Products
10.4.4 Recent Developments
10.5. Dendreon Pharmaceuticals LLC
10.5.1 Company Overview
10.5.2 Company Revenue
10.5.3 Products
10.5.4 Recent Developments
10.6. Dynavax Technologies Corporation
10.6.1 Company Overview
10.6.2 Company Revenue
10.6.3 Products
10.6.4 Recent Developments
10.7. Ferring B.V.
10.7.1 Company Overview
10.7.2 Company Revenue
10.7.3 Products
10.7.4 Recent Developments
10.8. Amgen Inc.
10.8.1 Company Overview
10.8.2 Company Revenue
10.8.3 Products
10.8.4 Recent Developments
10.9. Moderna Inc.
10.9.1 Company Overview
10.9.2 Company Revenue
10.9.3 Products
10.9.4 Recent Developments
10.10. Sanofi
10.10.1 Company Overview
10.10.2 Company Revenue
10.10.3 Products
10.10.4 Recent Developments
10.11. AstraZeneca
10.11.1 Company Overview
10.11.2 Company Revenue
10.11.3 Products
10.11.4 Recent Developments
10.12. Bristol Myers Squibb
10.12.1 Company Overview
10.12.2 Company Revenue
10.12.3 Products
10.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies
